Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;24(12-13):e2300002.
doi: 10.1002/pmic.202300002. Epub 2023 Dec 24.

Integration of proteomics in the molecular tumor board

Johanna Thiery  1 , Matthias Fahrner  1   2
Affiliations
Review

Integration of proteomics in the molecular tumor board

Johanna Thiery et al. Proteomics. 2024 Jun.

Abstract

Cancer remains one of the most complex and challenging diseases in mankind. To address the need for a personalized treatment approach for particularly complex tumor cases, molecular tumor boards (MTBs) have been initiated. MTBs are interdisciplinary teams that perform in-depth molecular diagnostics to cooperatively and interdisciplinarily advise on the best therapeutic strategy. Current molecular diagnostics are routinely performed on the transcriptomic and genomic levels, aiming to identify tumor-driving mutations. However, these approaches can only partially capture the actual phenotype and the molecular key players of tumor growth and progression. Thus, direct investigation of the expressed proteins and activated signaling pathways provide valuable complementary information on the tumor-driving molecular characteristics of the tissue. Technological advancements in mass spectrometry-based proteomics enable the robust, rapid, and sensitive detection of thousands of proteins in minimal sample amounts, paving the way for clinical proteomics and the probing of oncogenic signaling activity. Therefore, proteomics is currently being integrated into molecular diagnostics within MTBs and holds promising potential in aiding tumor classification and identifying personalized treatment strategies. This review introduces MTBs and describes current clinical proteomics, its potential in precision oncology, and highlights the benefits of multi-omic data integration.

Keywords: molecular diagnostics; molecular tumor board; personalized medicine; precision medicine; proteomics.

PubMed Disclaimer

References

REFERENCES

    1. Luchini, C., Lawlor, R. T., Milella, M., & Scarpa, A. (2020). Molecular tumor boards in clinical practice. Trends in Cancer, 6(9), 738–744. https://doi.org/10.1016/j.trecan.2020.05.008
    1. Schwaederle, M., Parker, B. A., Schwab, R. B., Fanta, P. T., Boles, S. G., Daniels, G. A., Bazhenova, L. A., Subramanian, R., Coutinho, A. C., Ojeda‐Fournier, H., Datnow, B., Webster, N. J., Lippman, S. M., & Kurzrock, R. (2014). Molecular tumor board: The University of California San Diego Moores Cancer Center Experience. The Oncologist, 19(6), 631–636. https://doi.org/10.1634/theoncologist.2013‐0405
    1. Dalton, W. B., Forde, P. M., Kang, H., Connolly, R. M., Stearns, V., Gocke, C. D., Eshleman, J. R., Axilbund, J., Petry, D., Geoghegan, C., Wolff, A. C., Loeb, D. M., Pratilas, C. A., Meyer, C. F., Christenson, E. S., Slater, S. A., Ensminger, J., Parsons, H. A., Park, B. H., & Lauring, J. (2017). Personalized medicine in the oncology clinic: Implementation and outcomes of the Johns Hopkins molecular tumor board. JCO Precision Oncology, 1, 1–19. https://doi.org/10.1200/PO.16.00046
    1. Hoefflin, R., Geißler, A.‐L., Fritsch, R., Claus, R., Wehrle, J., Metzger, P., Reiser, M., Mehmed, L., Fauth, L., Heiland, D. H., Erbes, T., Stock, F., Csanadi, A., Miething, C., Weddeling, B., Meiss, F., Von Bubnoff, D., Dierks, C., Ge, I., … Von Bubnoff, N. (2018). Personalized clinical decision making through implementation of a molecular tumor board: A German single‐center experience. JCO Precision Oncology, 2, 1–16. https://doi.org/10.1200/PO.18.00105
    1. Ortiz, M. V., Kobos, R., Walsh, M., Slotkin, E. K., Roberts, S., Berger, M. F., Hameed, M., Solit, D., Ladanyi, M., Shukla, N., & Kentsis, A. (2016). Integrating genomics into clinical pediatric oncology using the molecular tumor board at the memorial Sloan Kettering cancer center: Pediatric molecular tumor board in clinical oncology. Pediatric Blood & Cancer, 63(8), 1368–1374. https://doi.org/10.1002/pbc.26002

Substances

LinkOut - more resources